One concept, three implementations of 3D pharmacophore-based virtual screening: Distinct coverage of chemical search space

Journal of Chemical Information and Modeling

Volumn 50, Issue 7, 2010, Pages 1241-1247

  Spitzer, Gudrun M ^a   Heiss, Mathias ^b   Mangold, Martina ^c   Markt, Patrick ^b   Kirchmair, Johannes ^b   Wolber, Gerhard ^b   Liedl, Klaus R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APPLICATION PROGRAMS; VIRTUAL REALITY;

CHEMICAL SEARCHES; CHEMICAL SPACE; DRUG DISCOVERY; MOLECULAR MODELING SOFTWARE; PHARMACOPHORE MODELING; SEARCH STRATEGIES; VIRTUAL DATABASE; VIRTUAL SCREENING;

PHARMACODYNAMICS;

DRUG; HEAT SHOCK PROTEIN 90;

ARTICLE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN;

DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 78049422919     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci100136b     Document Type: Article

References (36)

1. Pharmacophores and Pharmacophore Searches; Langer, T., Hoffmann, R. D., Eds.; WILEY-VCH Verlag GmbH: Weinheim, Germany, 2006.
2. Leach, A. R.; Gillet, V. J.; Lewis, R. A.; Taylor, R. Three-Dimensional Pharmacophore Methods in Drug Discovery. J. Med. Chem. 2009, 53, 539-558.
3. Langer, T.; Hoffman, R. D. Virtual Screening: An Effective Tool for Lead Structure Discovery. Curr. Pharm. Des. 2001, 7, 509-527. (Pubitemid 32422003)
4. Langer, T.; Krovat, E. M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discovery Dev. 2003, 6, 370-376. (Pubitemid 36702310)
5. Mason, J. S.; Good, A. C.; Martin, E. J. 3-D Pharmacophores in Drug Discovery. Curr. Pharm. Des. 2001, 7, 567-597. (Pubitemid 32427655)
6. Greene, J.; Kahn, S.; Savoj, H.; Sprague, P.; Teig, S. Chemical Function Queries for 3D Database Search. J. Chem. Inf. Comput. Sci. 1994, 34, 1297-1308.
7. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discovery Today 2008, 13, 23-29.
8. Catalyst, version 4.11; Accelrys Inc.: San Diego, CA, 2005.
9. Discovery Studio, version 2.0; Accelrys Inc.: San Diego, CA, 2007.
10. Dixon, S.; Smondyrev, A.; Knoll, E.; Rao, S.; Shaw, D.; Friesner, R. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput.-Aided Mol. Des. 2006, 20, 647-671. (Pubitemid 46023928)
11. Phase, version 3.0; Schrödinger, LLC: New York, NY, 2007.
12. Maestro, version 8.3; Schrödinger, LLC: New York, NY, 2007.
13. Molecular Operating Environment (MOE), version 2008.10; Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2008.
14. Rohrer, S. G.; Baumann, K. Maximum Unbiased Validation (MUV) Data Sets for Virtual Screening Based on PubChem Bioactivity Data. J. Chem. Inf. Model. 2009, 49, 169-184.
15. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking Sets for Molecular Docking. J. Med. Chem. 2006, 49, 6789-6801. (Pubitemid 44749746)
16. Irwin, J. J.; Shoichet, B. K. ZINC-A Free Database of Commercially Available Compounds for Virtual Screening. J. Chem. Inf. Model. 2005, 45, 177-182. (Pubitemid 40736970)
17. Mahalingam, D.; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting HSP90 for cancer therapy. Br. J. Cancer 2009, 100, 1523-1529.
18. Hahn, J.-S. The Hsp90 chaperone machinery: from structure to drug development. BMB Reports 2009, 42, 623-630.
19. Sgobba, M.; Rastelli, G. Structure-Based and in silico Design of Hsp90 Inhibitors. ChemMedChem 2009, 4, 1399-1409.
20. Kim, Y. S.; Alarcon, S. V.; Lee, S.; Lee, M. J.; Giaccone, G.; Neckers, L.; Trepel, J. B. Update on Hsp90 Inhibitors in Clinical Trial. Curr. Top. Med. Chem. 2009, 9, 1479-1492.
21. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W.-C. Heat Shock Protein 90: Inhibitors in Clinical Trials. J. Med. Chem. 2010, 53, 3-17.
22. Buchanan, M. S.; Carroll, A. R.; Wessling, D.; Jobling, M.; Avery, V. M.; Davis, R. A.; Feng, Y.; Xue, Y.; Oster, L.; Fex, T.; Deinum, J.; Hooper, J. N. A.; Quinn, R. J.; Clavatadine, A. A Natural Product with Selective Recognition and Irreversible Inhibition of Factor XIa. J. Med. Chem. 2008, 51, 3583-3587. (Pubitemid 351875013)
23. Weis, D. C.; Visco, D. P., Jr.; Faulon, J.-L. Data mining PubChem using a support vector machine with the Signature molecular descriptor: Classification of factor XIa inhibitors. J. Mol. Graphics Modell. 2008, 27, 466-475.
24. Omega, version 2.0; OpenEye Scientic Software, Inc.: Santa Fe, NM, 2006.
25. LigandScout, version 2.02; Inte:Ligand: Vienna, Austria, 2009.
26. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters. J. Chem. Inf. Model. 2005, 45, 160-169. (Pubitemid 40736968)
27. Dixon, S. L.; Smondyrev, A. M.; Rao, S. N. PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching. Chem. Biol. Drue Des. 2006, 67, 370-372.
28. Homans, S. W. Dynamics and Thermodynamics of Ligand-Protein Interactions. Top. Curr. Chem. 2007, 272, 51-82.
29. Shoichet, B. K.; Leach, A. R.; Kuntz, I. D. Ligand solvation in molecular docking. Proteins: Struct., Funct., Genet. 1999, 34, 4-16. (Pubitemid 29019528)
30. Oellien, F.; Cramer, J.; Beyer, C.; Ihlenfeldt, W.-D.; Selzer, P. M. The Impact of Tautomer Forms on Pharmacophore-Based Virtual Screening. J. Chem. Inf. Model. 2006, 46, 2342-2354. (Pubitemid 46008109)
31. Laurence, C.; Brameld, K. A.; Graton, J.; Le Questel, J.-Y.; Renault, E. The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists. J. Med. Chem. 2009, 52, 4073-4086.
32. Kenny, P. W. Hydrogen Bonding, Electrostatic Potential, and Molecular Design. J. Chem. Inf. Model. 2009, 49, 1234-1244.
33. Böhm, H.-J.; Brode, S.; Hesse, U.; Klebe, G. Oxygen and Nitrogen in Competitive Situations: Which is the Hydrogen-Bond Acceptor. Chems.-Eur. J. 1996, 2, 1509-1513.
34. Phase 3.0 User Manual; Schrodinger, LLC: New York, NY, 2008.
35. Molecular Operating Environment (MOE), Version 2008.10, User Manual; Computing Group, Inc.: Montreal, Quebec, Canada, 2008.
36. Steindl, T. M.; Crump, C. E.; Hayden, F. G.; Langer, T. Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. J. Med. Chem. 2005, 48, 6250-6260. (Pubitemid 41428980)